Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026
Biogen announced it will present new data across its Alzheimer's disease portfolio at the CTAD conference on November 16-19, 2026 in Boston. Headline items include 96-week long-term extension data and additional 76-week biomarker and clinical data from the Phase 2 CELIA study of the tau-targeting ASO diranersen, plus five-year Clarity AD open-label extension and three-year real-world LEADER data for lecanemab.
Key figures
- Lte data weeks
- 96
- Celia enrollment
- 416
- Celia biomarker data weeks
- 76
- Lecanemab approved countries
- 53
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.